Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
He hoped to sell higher volumes of obesity and diabetes drugs over the coming years, saying: We are seeing a volume response to lower prices. He pointed to Novos agreement with the Trump administration to cut prices heavily, from more than $1,000 a month (730) to an average price of $350 (255), and the patent expiry of semaglutide, the main ingredient of its obesity and diabetes drugs, in several countries including India
The study found that the combination therapy resulted in a significant mean body weight reduction of 20.4% compared to 3.0% with placebo, and was superior to both monotherapies
It works by reducing appetite, increasing feelings of fullness, slowing gastric emptying, boosting insulin release when blood sugar is high, and reducing glucagon secretion
Some continue longer based on individual goals and physician assessment
BMJ 388:e080679
